secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0000950170-22-011518
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exa-cel shows 95% TDT transfusion-free; CTX130 achieves 70% ORR in T-cell lymphoma
--------------------------------------------------------------------------------

- 42 of 44 TDT patients transfusion-free; all 31 SCD patients free of VOCs; follow-up up to 37.2 months.
- Exa-cel primary endpoints amended: TDT target Hb ≥9 g/dL without transfusions; SCD target no severe VOCs.
- Pediatric exa-cel studies CLIMB-141/151 now enrolling patients ages 5-11 with TDT or SCD.
- CTX130 at DL3+: ORR 70% (30% CR) in PTCL/CTCL; 90% DCR; responses across all disease compartments.
- CTX130 well tolerated: no DLTs, no GvHD, all CRS/ICANS grade 1-2; no treatment-related deaths.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022011518/0000950170-22-011518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022011518/crsp-20220611.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer